Dr. Peter R. Mueller, Ph.D. served as the Chief Scientific Officer and President of Research & Development at Axcella Health, Inc. since December 4, 2014 until January 3, 2017. Dr. Mueller has more than 20 years of global experience in the Pharmaceutical industry. Dr. Mueller served the Chief Scientific Officer at Vertex Pharmaceuticals Incorporated from July 21, 2003 to October 31, 2014 and Executive Vice President of Global Research & Development from May 2009 to October 31, 2014. Dr. Mueller was responsible for research and drug discovery activities and directs research strategy across the Vertex Pharmaceuticals Inc.'s Cambridge, San Diego and Oxford, UK, sites. Dr. Mueller served as Senior Vice President of Research and Development of Boehringer Ingelheim Pharmaceuticals, Inc. since 1997, where he played a key role in the development of Spiriva®, Combivent®, and Atrovent®. Dr. Mueller joined Vertex Pharmaceuticals Incorporated in 2003 He served as Executive Vice President of Drug Discovery and Innovation at Vertex Pharmaceuticals Incorporated from February 2006 to May 2009 and its Senior Vice President of Drug Discovery and Innovation from July 21, 2003 to February 2006. Dr. Mueller joined Vertex from Boehringer Ingelheim Pharmaceuticals, he served as Chief Operating Officer and Director of Research at Amarillo Biosciences Inc. since April 15, 2008 until May 31, 2009. He was actively involved in the development of strategic alliances and business opportunities with other companies and organizations. Since April 2001 until joining Amarillo, Dr. Mueller served as President of Epicenter Consulting, Inc. He served as Vice President of Global Marketing & Medical Information and Technology for Aventis Pharmaceuticals. He served as Vice President of Global Business & Marketing Services for Hoechst Marion Roussel. He served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of its worldwide portfolio in North America. He led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. At Boehringer Ingelheim, Dr. Mueller oversaw the discovery of 12 development candidates, including: seven Phase I compounds, five Phase IIa candidates, three Phase IIb/III drug candidates and six new drug applications. Dr. Mueller began his career at Boehringer Ingelheim in 1984 where he held several positions in basic research, medicinal chemistry and management. He has been the Chairman of Scientific Advisory Board at BioXcel Corporation since October 12, 2016. He serves as a Director of Inhibikase Therapeutics, Inc. He serves on Board/Scientific Advisory Board of Kaleido Biosciences, Inc. He served as a Member of the Scientific Advisory Board at Vertex Pharmaceuticals Incorporated. He serves on several Boards and Scientific Advisory Board in companies and organizations including US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, University Iowa (CBB) and Keystone Symposia. Dr. Mueller is a member of various scientific and political societies, including Gesellschaft Deutscher Chemiker, Royal Society of Chemistry, Verband Chemische Industrie (Germany), IRI, The RNA Society, ASAP and the American Association for the Advancement of Science. He is a faculty member of Albert Einstein University of Ulm holding a professorship in theoretical organic chemistry. Dr. Mueller is named as an inventor on 43 filed and granted patents. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Dr. Mueller is a pharmacist with a Ph.D. degree in pharmaceuticals from the University of Mainz, Germany.

immunology, inflammation, cardiovascular disease and gene therapy